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Among gynecologic malignancies, ovarian cancer is the third most prevalent and
the most common cause of death, especially due to diagnosis at an advanced
stage together with resistance to therapy. As a solid tumor grows, cancer cells
in the microenvironment are exposed to regions of hypoxia, a selective pressure
prompting tumor progression and chemoresistance. We have previously shown that
cysteine contributes to the adaptation to this hypoxic microenvironment, but the
mechanisms by which cysteine protects ovarian cancer cells from hypoxia-induced
death are still to be unveiled. Herein, we hypothesized that cysteine contribution
relies on cellular metabolism reprogramming and energy production, being cysteine
itself a metabolic source. Our results strongly supported a role of xCT symporter
in energy production that requires cysteine metabolism instead of hydrogen sulfide
(H2S) per se. Cysteine degradation depends on the action of the H2S-synthesizing
enzymes cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and/or 3-
mercaptopyruvate sulfurtransferase (MpST; together with cysteine aminotransferase,
CAT). In normoxia, CBS and CSE inhibition had a mild impact on cysteine-sustained ATP
production, pointing out the relevance of CAT + MpST pathway. However, in hypoxia,
the concomitant inhibition of CBS and CSE had a stronger impact on ATP synthesis,
thus also supporting a role of their hydrogen sulfide and/or cysteine persulfide-
synthesizing activity in this stressful condition. However, the relative contributions of each
of these enzymes (CBS/CSE/MpST) on cysteine-derived ATP synthesis under hypoxia
remains unclear, due to the lack of specific inhibitors. Strikingly, NMR analysis strongly
supported a role of cysteine in the whole cellular metabolism rewiring under hypoxia.
Additionally, the use of cysteine to supply biosynthesis and bioenergetics was reinforced,
bringing cysteine to the plateau of a main carbon sources in cancer. Collectively,
this work supports that sulfur and carbon metabolism reprogramming underlies the
adaptation to hypoxic microenvironment promoted by cysteine in ovarian cancer.
Keywords: carbon source, cysteine, hypoxia, ovarian cancer, hydrogen sulfide, cystine, bioenergetics,
microenvironment
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INTRODUCTION
Despite all the progresses developed in prevention and new
treatment approaches, cancer corresponds to the second leading
cause of death worldwide (Fitzmaurice et al., 2015). Ovarian
cancer is not an exception to this scenario, being expected, in
2020, 0.28 million new cases and 0.18 million ovarian cancer
deaths worldwide (Ferlay et al., 2013). The late diagnosis together
with resistance to conventional therapy represent the major
causes for the poor prognosis of this disease (Jayson et al., 2014).
Epithelial ovarian cancer (EOC) includes most (90%) ovarian
malignancies (Bast et al., 2009; Desai et al., 2014) that can
be classified based on histopathology and molecular/genetic
features, being mainly classified as serous low-grade (LG-OSC,
<5%) and high-grade (HG-OSC, 70%), endometrioid (OEC,
10%), clear cell (OCCC, 10%) and mucinous (OMC, 3%) (Prat,
2012; Reid et al., 2017).
As a solid tumor grows, cancer cells are exposed to
varying oxygen tensions and to different degrees of hypoxia,
being these oxygen fluctuations strongly linked to oxidative
stress (Fruehauf and Meyskens, 2007; Saed et al., 2017) and
known to be responsible for tumor progression and resistance
to therapy (Vaupel and Mayer, 2007; Semenza, 2012). In
ovarian cancer, oxidative stress was already associated with the
pathogenesis of the disease (Senthil et al., 2004; Saed et al.,
2017), indicating that ovarian cancer cells present mechanisms
that allow them to cope with the harmful oxidative conditions.
We disclosed that cysteine facilitates the adaptation of ovarian
cancer cells to hypoxic environments and to carboplatin-induced
death (Nunes et al., 2018a,b). Moreover, the relevance of
cysteine in the clinical context of ovarian cancer was also
corroborated, since ascitic fluid from ovarian cancer patients –
an important compartment of tumor microenvironment –
showed cysteine as the prevalent thiol and because cysteine
levels were also altered in serum from patients with ovarian
tumors (Nunes et al., 2018b). Cysteine role in cancer cells
survival was already associated with its role as a precursor of
the antioxidant glutathione (GSH) (Schnelldorfer et al., 2000;
Balendiran et al., 2004; Lopes-Coelho et al., 2016) and due
to hydrogen sulfide (H2S) generation (Bhattacharyya et al.,
2013; Szabo et al., 2013; Pan et al., 2015; Panza et al., 2015;
Sen et al., 2015; Gai et al., 2016; Szczesny et al., 2016)
by cysteine catabolism through the activity of the enzymes
cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE),
and/or 3-mercapto-pyruvate sulfurtransferase (MpST) together
with cysteine aminotransferase (CAT) (Wang, 2012; Kabil and
Banerjee, 2014; Giuffrè and Vicente, 2018; Hipólito et al., 2020).
CBS, CSE, and MpST also catalyze the cyst(e)ine-dependent
production of cysteine persulfide (CysSSH), which in several
(patho)physiological contexts affords protection from damaging
cysteine oxidation (e.g., Filipovic et al., 2018; Zivanovic et al.,
2019; Zuhra et al., 2021). Another recently proposed pathway
linking cysteine catabolism with mitochondrial bioenergetics
concerns the mitochondrial isoform of cysteinyl-tRNA synthase
(CARS2), which converts cysteine into CysSSH and also
incorporates persulfidated cysteine into nascent polypeptides
(Akaike et al., 2017; Bianco et al., 2019). The uptake of cysteine
by cells seems to be preferentially mediated by xCT, a member of
the cystine-glutamate transporter xc- system, known to mediate
the uptake of cystine, the oxidized form of cysteine (Sato et al.,
2000). Interestingly, it was reported that xCT was associated
with intracellular GSH level and with cisplatin resistance in
human ovarian cancer cell lines (Okuno et al., 2003). More
recently, xCT has been implicated as part of highly favorable
metabolic cancer phenotype, presenting increased capacity of
ATP generation amongst other features pivotal for cancer cells
survival and chemoresistance (Polewski et al., 2016; Jourdain
et al., 2021).
Here, we aimed to address the mechanism by which cysteine
protects ovarian cancer cells from hypoxia-induced death,
hypothesizing that in addition to its role as GSH precursor,
cysteine contributes to cell bioenergetics and biosynthesis under
hypoxic conditions, as both a donor of H2S and as a carbon
source. To test this hypothesis, we used two different ovarian
cancer cell lines derived from two different histological types. ES2
cells correspond to an ovarian clear cell carcinoma (OCCC), an
uncommon but highly chemoresistant histotype, and OVCAR3
cells correspond to a high-grade ovarian serous carcinoma
(HG-OSC, the most frequent histotype), which usually acquires
resistance during chemotherapy (Goff et al., 1996; Sugiyama et al.,
2000; Cooke et al., 2011; Beaufort et al., 2014).
MATERIALS AND METHODS
Cell Culture
Cell lines from OCCC (ES2; CRL-1978) and HG-OSC (OVCAR-
3; HTB-161) were obtained from American Type Culture
Collection (ATCC). Cells were maintained at 37◦C in a
humidified 5% CO2 atmosphere, and cultured in Dulbecco’s
Modified Eagle medium (DMEM, 41965-039, Gibco, Life
Technologies), containing 4.5 g/L of D-glucose and 0.58 g/L of
L-glutamine, 1% FBS (S 0615, Merck), 1% antibiotic-antimycotic
(P06-07300, PAN Biotech) and 0.1% gentamicin (15750-060,
Gibco, Life Technologies). Cells were exposed either to 0.402 mM
L-cysteine (102839, Merck) and/or to hypoxia induced with
0.1 mM cobalt chloride (CoCl2) (C8661, Sigma-Aldrich) as
previously (Nunes et al., 2018a,b).
Prior to any experiment, cells were synchronized under
starvation (culture medium without FBS) for 8 h at 37◦C
and 5% CO2.
ATP Quantification
To test the effect of xCT inhibition on ATP levels, cells (5 × 105
or 2.5 × 105 cells/well) were seeded in 6-well white plates in
hypoxia-mimic conditions induced with 0.1 mM CoCl2 and
challenged with 0.25 mM sulfasalazine (S0883, Sigma), an xCT
inhibitor (Gout et al., 2001). After 24 h, the medium was replaced
and the challenging/stimulatory conditions reset. Cells were
collected at 48 h after stimulation.
To test the effect of the enzymes involved in cysteine
metabolism on ATP synthesis, cells (5 × 105 or 2.5 × 105
cells/well) were seeded in 6-well plates and cultured in control
condition and exposed to 0.402 mM L-cysteine and/or 0.100 mM
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CoCl2. The previous conditions were combined with 1 mM
O-(carboxymethyl)hydroxylamine hemihydrochloride (AOAA,
C13408, Sigma) and 3 mM DL-propargylglycine (PAG, P7888,
Sigma). AOAA is an inhibitor of both CBS and CSE, whereas PAG
is selective toward CSE. After 24 h, the medium was replaced and
the challenging/stimulatory conditions reset. Cells were collected
at 16 and 48 h after stimulation. This assay was also performed
with cell collection after 2 h of experimental conditions. In this
case, 5× 105 cells were seeded in 6-well white plates for both ES2
and OVCAR3 cells.
To investigate the effect of cyst(e)ine and NaHS (H2S donor)
on ATP synthesis upon xCT inhibition, cells (5 × 105 or
2.5 × 105 cells/well) were seeded in 6-well plates and exposed
to hypoxia induced with 0.1 mM CoCl2 with and without
0.402 mM L-cysteine combined with 0.25 mM sulfasalazine,
30 µM NaHS (161527 Sigma-Aldrich) or both. After 24 h, the
medium was replaced and the challenging/stimulatory conditions
reset. Cells were collected at 48 h after stimulation. This assay
was also performed with cell collection after 1 h of experimental
conditions. In this case, 5× 105 cells were seeded in 6-well white
plates for both ES2 and OVCAR3 cells.
Cells were scraped with cold PBS containing 2 mM
EDTA and homogenized in 1% Non-idet P-40 (NP-40) lysis
buffer (1% NP40 N-6507 Sigma, and 1× protease inhibitor,
SIGMAFASTTM Protease inhibitor cocktail tablets S8830, Sigma)
on ice for 30 min and centrifuged at 20,000 × g for 5 min
at 4◦C. Protein was quantified and the same amount of
total protein was used within each assay, in a range between
2.5 and 10 µg. ATP determination kit (A22066, Molecular
probes) was used in accordance with the manufacturer’s
instructions. The measurements were performed using the
Luciferase protocol in a VIKTOR3 plate reader (PerkinElmer),
using the Wallac 1420 software, version 3.0 (Luminometry,
Luciferase FIR protocol). ATP concentration was determined
against an ATP calibration curve, within the range between 0
and 30 µM.
Immunofluorescence Analysis
Cells (1 × 105 cells/well) were seeded in 24-well plates and
cultured either in control or stimulated/challenged conditions.
After 16 h of experimental conditions, cells were fixed with
4% paraformaldehyde for 15 min at 4◦C and permeabilized
with saponin 0.1% in PBS-BSA (PBS buffer containing 0.5%,
w/v, bovine serum albumin) for 15 min at room temperature.
Cells were then incubated with anti-xCT (ab175186, abcam)
for 30 min (diluted 1:100 in PBS-BSA) and incubated with
secondary antibody for 2 h at room temperature (Alexa Fluor R©
488 anti-rabbit, A-11034, Invitrogen) (1:1000 in PBS-BSA). The
protocol was repeated for anti-TOMM20 (1:100 in PBS PBS-
BSA; ab186734 from abcam) for 2 h at room temperature
and incubated with secondary antibody for 2 h at room
temperature (Alexa Fluor R©594 anti-rabbit, A-11037, Invitrogen)
(1:1000 in PBS-BSA).
The slides were mounted in VECTASHIELD media with
4′-6-diamidino-2-phenylindole (DAPI) (Vector Labs) and
examined by standard fluorescence microscopy (Zeiss Imajer.Z1
AX10 microscope). Images were acquired and processed with
CytoVision software.
Western Blotting Analysis of
Mitochondria Extracts
Cells (7 × 106 cells/flask) were cultured in 150 cm2 culture
flasks and submitted to control condition and to 0.402 mM
L-cysteine and/or 0.1 mM CoCl2. Cells were collected after
16 h of experimental conditions, and mitochondria were isolated
with the Mitochondria Isolation Kit for profiling cultured cells
(MITOISO2, Sigma). Briefly, cells were scraped, centrifuged for
5 min at 600 × g and washed in ice cold PBS. The cell pellet
was resuspended in 650 µL of Lysis Buffer, according to the
manufacturer’s instructions.
The mitochondrial lysates were centrifuged at 20,817 × g for
5 min at 4◦C and total protein concentration was determined
based on the Bradford method (500-0006, Bio Rad). Western
blotting for xCT and TOMM20 detection was performed with
15 µg of total protein, whereas for MpST, 20 µg of total
protein were used. TOMM20 was used as a mitochondrial
endogenous control.
Total protein in SDS-PAGE gels was transferred to
PVDF membranes by semi-dry transfer. Membranes were
blocked with PBS-milk (PBS containing 5% non-fat skimmed
powdered milk) incubated with anti-xCT (1:1000 in PBS-milk;
ab175186 from abcam) or anti-MpST (1:250 in PBS-milk;
HPA001240 from Sigma) at 4◦C with stirring, overnight. The
membranes were then washed three times, for 5 min, with
PBS 1 × 0.1% (v/v) Tween 20, and further incubated with
secondary antibody (anti-rabbit 1:5,000 in PBS-milk; 31460
from Thermo Scientific) for 2 h at room temperature. For the
membrane that was previously incubated with xCT, the protocol
was repeated for anti-TOMM20 (1:1000 in PBS 1x-Milk 5%;
ab186734 from abcam).
Cell Death Analysis
To test whether the protective effect of cysteine under
hypoxia was dependent on H2S production, cells (1 × 105
cells/well) were seeded in 24-well plates. Cells were cultured in
control condition and exposed to 0.402 mM L-cysteine and/or
hypoxia induced with 0.1 mM CoCl2, combined to 1 mM
O-(carboxymethyl)hydroxylamine hemihydrochloride (AOAA,
C13408, Sigma), to 3 mM of DL-propargylglycine (PAG, P7888,
Sigma), or the combination of both. Cells were collected 16 h after
stimulation.
Cells were harvested by centrifugation at 153 × g for 3 min,
cells were incubated with 0.5 µL FITC-Annexin V (640906,
BioLegend) in 100 µL annexin V binding buffer 1 × 10 mM
HEPES (pH 7.4), 0.14 M sodium chloride (NaCl), 2.5 mM
calcium chloride (CaCl2) and incubated at room temperature and
in the dark for 15 min. After incubation, samples were rinsed with
0.2% (w/v) BSA (A9647, Sigma) in PBS and centrifuged at 153× g
for 3 min. Cells were suspended in 200 µL of annexin V binding
buffer 1× and 2.5 µL propidium iodide (50 µg/mL) were added.
Acquisition was performed in a FACScalibur (Becton Dickinson).
Data were analyzed with FlowJo software.
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Nuclear Magnetic Resonance (NMR)
Analysis
To address the metabolic effects of cysteine under normoxia
and hypoxia in ES2 and OVCAR3 cells, the levels of several
metabolites were measured by 1H-NMR. Cells (6.5 × 106 cells)
were seeded in 175 cm2 culture flasks and cultured in control
condition and exposed to 0.402 mM L-cysteine and/or hypoxia-
mimicked conditions induced with 0.1 mM CoCl2. Cells and
supernatants were collected at 48 h after stimulation and stored
at−20◦C.
To follow all the metabolites directly derived from cysteine,
cells (6.5 × 106 cells) were seeded in 175 cm2 culture flasks
and cultured in control condition and exposed to 0.402 mM
L-cysteine and/or hypoxia induced with 0.1 mM CoCl2. In
this assay, a fully U-13C-labeled L-cysteine (CLM-1868-PK,
Cambridge Isotopes Laboratories, Inc.) was used. Cells were
collected at 48 h after stimulation and supernatants were collected
at 12, 24, 36, and 48 h of incubation and stored at−20◦C.
Cell extracts were performed with methanol and chloroform
to separate organic and aqueous phases. After cold methanol
mixture (4 mL methanol/1 g weight pellet), two volumes (vol)
of water were added, mixed, and incubated for 5 min on ice.
Chloroform (1 vol) was then added to the sample and mixed.
Finally, 1 vol of water was added and samples were incubated
for 10 min on ice, following centrifugation at 1,699 × g for
15 min at 4◦C. Aqueous (upper) and organic (lower) phases were
collected. After extraction of solvents by evaporation, using a
Speed Vac Plus Scllon, the samples were suspended on KPi buffer
(50 mM, pH 7.4) in deuterated water (D2O) with 4% (v/v) sodium
azide (NaN3) and 0.097 mM of 3-(trimethylsilyl)propionic-
2,2,3,3-d4 (TSP). Culture supernatants were also diluted in
this solution at 1:10 ratio. The 1H-NMR (noesypr1d), 13C-
NMR (zgdc) and 13C-1H-HSQC (hsqcetgpsisp2) was obtained
at 25◦C in an Avance 500 II+ (Bruker) spectrometer operating at
500.133 MHz, equipped with a 5 mm TCI(F)-z H-C/N Prodigy
cryo-probe. The chemical shifts in aqueous sample were referred
to the TSP. Topspin 4.0.7 (Bruker) was used for acquisition
and spectra analysis. Compound identification was performed
by resorting to the Human Metabolome database (HMDB)1
and Chenomx NMR suite software version 8.1 (Chenomx Inc.).
Metabolites concentration was determined using Chenomx NMR
suite software version 8.1 for 1H-NMR spectra (Chenomx Inc.).
Quantification of the resonances in 13C-1H-HSQC spectra
was done by calculate the 1D projections and integrate the
resonances areas in Topspin 4.0.7, using the TSP resonance was
reference.
Statistical Analysis
All data are presented as the mean ± SD with the exception of
1H-NMR data, which are presented as the median with 25th to
75th percentiles. All the graphics were done using the PRISM
software package (PRISM 6.0 for Mac OS X; GraphPad software,
United States, 2013) and Microsoft Excel. Assays were performed
with at least three biological replicates per treatment, with the
1http://www.hmdb.ca/
exception of NMR assay with 13C-labeled L-cysteine for which
only two biological replicates were performed for the majority of
treatments, and hence no statistical analysis was conducted. For
comparisons of two groups, a two-tailed independent-samples
t-test was used. For comparison of more than two groups,
one-way analysis of variance (ANOVA) with Tukey’s multiple-
comparisons post hoc test was used. Statistical significance was
established as p < 0.05. All statistical analyses were performed
using the IBM Corp. Released 2013. IBM SPSS Statistics for
Macintosh, Version 22.0. Armonk, NY: IBM Corp. software, with
the exception of metabolic pathway analysis that was performed
with MetaboAnalyst 4.02.
RESULTS
xCT Transporter Localizes in Ovarian
Cancer Cells’ Mitochondria and Its
Inhibition Impairs ATP Production Under
Hypoxia, Which Is Further Rescued by
Cysteine Supplementation
We have previously reported that cysteine supplementation was
able to protect ovarian cancer cells from hypoxia-induced death
(Nunes et al., 2018a,b). Herein, we hypothesized that an increase
in intracellular cysteine facilitates this adaptation to hypoxia by
an increase in ATP production.
Results show that after 16 h of experimental conditions,
for ES2 cells, ATP levels did not differ among hypoxia with
and without cysteine supplementation, and were higher under
hypoxia without cysteine compared to normoxia with cysteine
(p = 0.017) (Figure 1A). With 48 h of experimental conditions,
ATP levels were increased under hypoxia without cysteine
compared both to hypoxia (p = 0.018) and normoxia (p = 0.033)
with cysteine (Figure 1A).
In OVCAR3 cells, after 16 h of experimental conditions,
no differences were observed among treatments (Figure 1B).
However, with 48 h of experimental conditions, the results were
identical to ES2 cells, where cells cultured under hypoxia without
cysteine presented higher ATP levels compared both to normoxia
(p = 0.008) and hypoxia (p < 0.001) with cysteine (Figure 1B).
Therefore, after 48 h of experimental conditions, we observed
increased ATP levels in hypoxia-mimicked conditions, which
were prevented by cysteine administration in both ES2 and
OVCAR3 (Figures 1A,B). These results support that ovarian
cancer cells exhibit alternative ways that allow sustaining energy
production under hypoxic environments. Since cells cultured
under hypoxia without cysteine supplementation also present
cysteine in the medium (yet in lower concentrations), and
also because cells cultured under hypoxia with cysteine reach
higher cellular confluence levels compared to hypoxia without
cysteine, we cannot, nevertheless, rule out a role of cysteine
in ATP production. Therefore, we further explored the role
of xCT, a member of the cystine-glutamate transporter xc-
system, known to mediate the uptake of cystine (Sato et al., 2000)
2https://www.metaboanalyst.ca/faces/home.xhtml
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 August 2021 | Volume 9 | Article 722412
fcell-09-722412 August 11, 2021 Time: 12:37 # 5
Nunes et al. Cancer Dependence on Cysteine Metabolism
FIGURE 1 | xCT transporter localizes in ovarian cancer cells’ mitochondria and its inhibition impairs ATP production under hypoxia, which is further rescued by
cysteine. ATP levels normalized to control values (normoxia without cysteine supplementation) for 16 h and 48 h of experimental conditions for (A) ES2 cells and
(B) OVCAR3 cells. The differences among treatments are pointed in the figure (one-way ANOVA with post hoc Tukey tests. For ES2, n = 6 for all treatments for 16 h
of experimental conditions and n = 3 for 48 h of experimental conditions. For OVCAR3, n = 6 for all experimental conditions). (C) Immunofluorescence analysis for
the xCT transporter and TOMM20 under control conditions (normoxia) for ES2 and OVCAR3 cells (n = 3). (D) ATP levels for 48 h of experimental conditions for ES2
and OVCAR3 cells under hypoxia and in the presence of the xCT inhibitor, sulfasalazine. (E) ATP levels for 48 h of experimental conditions for ES2 and OVCAR3 cells
under hypoxia and in the presence of sulfasalazine and cysteine. The values were normalized to the respective control and log2 fold change was calculated. The
differences among treatments are pointed in panels (D,E) (independent-samples t-test; n = 6 for all experimental conditions and for both cell lines). N, normoxia; NC,
normoxia with cysteine; H, hypoxia; HC, hypoxia with cysteine. Results are shown as mean ± SD. */#p < 0.05, **/##p < 0.01, ***/###p < 0.001.
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(the oxidized form of cysteine that is the predominant status
of cysteine extracellularly), on ATP production under hypoxic
environments. Thus, we started by addressing if this transporter
could localize in ovarian cancer cells’ mitochondria thus
suggesting a role of cysteine metabolism in ATP production
via xc- system. Immunofluorescence analysis suggested a
mitochondrial localization of xCT in both ES2 and OVCAR3
cells (Figure 1C) that was further confirmed by western blotting
analysis mitochondrial extracts (Supplementary Figure 1A).
Interestingly, by western blotting with anti-TOMM20 (a
mitochondrial marker) results show that ES2 cells present
higher levels of TOMM20 under hypoxia compared to the
other experimental conditions, whereas OVCAR3 cells seem
to present the opposite tendency. As a consequence, the
ratio xCT/TOMM20 was decreased under hypoxia-mimicked
conditions in ES2 cells and increased in OVCAR3 cells
(Supplementary Figure 1A).
We then explored the effect of xCT inhibition (with
sulfasalazine) in the ability of ovarian cancer cells to produce ATP
under hypoxia. Strikingly, xCT inhibition led to impaired ATP
production in both cell lines (p = 0.038 for ES2 and p = 0.010 for
OVCAR3) (Figure 1D). Importantly, cysteine was able to rescue
this impaired ATP production upon xCT inhibition. Hence,
we observed a significant increase in ATP levels upon cysteine
supplementation (p < 0.001) (Figure 1E).
CBS and CSE Inhibition Does Not Impair
ATP Synthesis but Induces Cell Death in
ES2 Cells
Since results suggested that cysteine has a role in ATP synthesis
mediated by the xCT transporter, we next measured ATP levels
upon CBS and CSE inhibition. Results have shown that after
16 h of experimental conditions, no differences were found in
ATP levels with or without CSE (PAG) and CBS/CSE inhibitors
(AOAA) for both ES2 and OVCAR3 cells in any culture condition
(Figures 2A–D). As in Figure 1, prolonged (48 h) exposure to
hypoxia of both ES2 and OVCAR3 cells resulted in increased
ATP production. However, under the same conditions, cysteine
decreased ATP levels in both cell lines. Given the dual nature
of H2S as an electron supply for the mitochondrial ETC at low
concentrations, or as an inhibitor of Complex IV at higher levels,
this observation further suggests that exogenous cysteine affects
ATP production via CBS/CSE-catalyzed H2S production.
Strikingly, upon exposure to CBS/CSE inhibitors for 48 h,
increased ATP levels were observed in all experimental
conditions for both ES2 (N p = 0.002, NC p = 0.001, H
p = 0.004, HC p = 0.001) and OVCAR3 cells (N, NC and HC
p < 0.0001 and H p = 0.003) with respect to their respective
controls (48 h, no inhibitors; Figures 2A–D). In both cell lines
exposed for 48 h to CBS/CSE inhibitors, hypoxia decreased
significantly ATP production as compared to normoxia, but
cysteine rescued this phenomenon (Figures 2B,D). These
observations support the relevance of cysteine degradation on
ATP production under hypoxia and put forward the possibility
of a compensatory mechanism, e.g., via CAT/MpST or CARS2 to
sustain H2S/CysSSH production under hypoxic conditions.
As ATP levels may increase under stressful conditions (e.g.,
Zhou et al., 2012) we investigate if there was an increase of
cell death in the presence of CSE (PAG) and CBS + CSE
(AOAA) inhibitors. We found that for ES2 cells, under normoxia
both with and without cysteine supplementation (N and NC),
CSE inhibition induced more cell death compared to joint
CSE/CBS inhibition (p = 0.017) (Figure 2E). Under hypoxia
(H), the combination of both inhibitors induced more cell
death compared to their separate administration (p < 0.001).
Interestingly, under hypoxia with cysteine, PAG alone resulted in
increased cell death (p = 0.038 compared to the control) as well as
in combination with AOAA (p = 0.002 compared to the control
and p = 0.01 compared to AOAA alone) (Figure 2E). Regarding
OVCAR3 cells, no differences were observed among treatments,
with or without the inhibitors and/or cysteine (Figure 2F).
Together, results indicate that CBS and CSE inhibition, at least
at the used doses, is not sufficient to impair ATP production but
the inhibition of both enzymes affected ATP synthesis mainly
under hypoxia for both cell lines. The role of MpST could not
be addressed as no specific inhibitor is available.
Moreover, ES2 cells showed reduced viability upon the
inhibition of both CBS and CSE under hypoxia-mimicked
conditions, showing that ES2 cells are especially sensitive
to the inhibition of these enzymes in this experimental
condition, highlighting their role in hypoxia adaptation and
the contribution of cysteine non-oxidative catabolism for cell
survival in conditions of hypoxic stress.
Cysteine Degradation Is Necessary to
Rescue ATP Production Triggered by
xCT Inhibition
Since results have suggested that cysteine has a role in ATP
production under hypoxia-mimicked conditions that can be in
part related to H2S synthesis, we investigated if the impact of
cysteine on ATP production rely on CBS/CSE-catalyzed H2S
production. For that we ascertained if cysteine metabolism was
necessary or if a bolus addition of an H2S donor, as NaHS, would
be sufficient to counteract the ATP impairment triggered by xCT
inhibition, both at short (1 h) and long (48 h) exposure times.
Due to the unstable nature of NaHS that was reported
in culture medium (Sun et al., 2017) leading to an instant
release of H2S that decays rapidly (Hu et al., 2011), we
evaluated ATP levels upon NaHS exposure for 1 h in
the experimental conditions tested before. Fu et al. (2012)
have reported that in vascular smooth-muscle cells, 1 h of
NaHS exposure was sufficient to alter mitochondrial ATP
production under hypoxia in a concentration-dependent manner,
consistently with the dual stimulatory/inhibitory nature of H2S
for mitochondrial bioenergetics.
In hypoxic ES2 cells, within 1 h of conditions, while
sulfasalazine alone tended to promote a slight increase in ATP
(Figure 3A), 30 µM NaHS alone led to decreased ATP levels
(p = 0.047) (Figure 3C), even upon xCT inhibition (H NaHS
vs. H sulfasalazine p < 0.001; H NaHS + sulfasalazine vs.
H sulfasalazine p < 0.001; HC NaHS vs. HC sulfasalazine
p = 0.002; HC NaHS + sulfasalazine vs. HC sulfasalazine
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FIGURE 2 | CBS and CSE inhibition does not impair ATP synthesis in ovarian cancer cells but affect ES2 cells survival, mainly in hypoxia-mimicked conditions. (A–D)
ATP levels in the presence of 1 mM AOOA and 3 mM PAG for 16 h and 48 h of experimental conditions for ES2 [A – values normalized to control (normoxia without
cysteine and without inhibitors) and (B) – values normalized to the respective control and log2 fold change calculation] and OVCAR3 [C – values normalized to
control (normoxia without cysteine and without inhibitors) and (D) – values normalized to the respective control and log2 fold change calculation] cells. (A,C) The
asterisks (*) represent the statistical significance compared to the respective control. (B,D) The asterisks (*) represent the statistical significance compared to N, the
section symbols (§) represents the statistical significance compared to NC and the cardinals (#) represent statistical significance compared to HC. For ES2, n = 6 for
all treatments for 16 h of experimental conditions and n = 3 for 48 h of experimental conditions. For OVCAR3, n = 6 for all experimental conditions. (E,F) Cell death
levels in the control condition, in the presence of CBS/CSE inhibitor (1 mM AOAA), CSE inhibitor (3 mM PAG) or both inhibitors for ES2 (E) and OVCAR3 (F) cells.
The asterisks (*) represent statistical significance between the respective treatments or between AOAA + PAG and its control, the cardinals (#) represent statistical
significance between AOAA + PAG and AOAA alone and the section symbols (§) represent statistical significance between AOAA + PAG and PAG alone. For both
cell lines, at least n = 6 were performed for all experimental conditions. N, normoxia; NC, normoxia with cysteine; H, hypoxia; HC, hypoxia with cysteine. Results are
shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 [(A,C) independent-samples t-test; (B,D–F) one-way ANOVA with post hoc Tukey tests].
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p < 0.001) (Figure 3A). In addition, under hypoxia with
cysteine supplementation, NaHS did not affect ATP production
(Figure 3C). For OVCAR3 cells, NaHS led to decreased ATP
levels both under hypoxia with (p = 0.002) and without cysteine
(p = 0.003) (Figure 3C), but no further differences were observed
among treatments (Figure 3B). Furthermore, while 1 h of
sulfasalazine was not sufficient to inhibit ATP levels in ES2
cells, there was a tendency for lower ATP levels in OVCAR3
cells (Figures 3A,B), suggesting that ES2 present higher basal
levels of the xCT transporter or that these cells activate xCT
(or other cysteine transporter) transcription in a more efficient
way compared to OVCAR3 cells. In fact, in basal conditions,
ES2 cells express higher xCT levels compared to OVCAR3 cells
(Supplementary Figure 1B), hence supporting that a more
prolonged exposure to sulfasalazine is necessary for the effective
blocking of xCT in ES2 cells.
While the 1 h of experimental conditions is suitable to
study NaSH effects, may not allow enough cysteine metabolism
to permit relevant H2S production. In fact, with 48 h of
experimental conditions, results have shown that whereas
cysteine was able to revert the ATP impairment upon xCT
inhibition in both ES2 and OVCAR3 cells (p < 0.001), NaHS
alone (H2S donor) was not, as no differences were found with
sulfasalazine with or without NaHS, for both cell lines (p > 0.05).
These results might indicate that H2S by itself does not rescue
ATP production, being cysteine degradation a requirement
(Figures 3D,E).
Cysteine Rescues Cellular Metabolism of
Hypoxic ES2 Cells
In order to address the metabolic effects of cysteine
supplementation under normoxia and hypoxia in ES2 and
OVCAR3 cells, we measured the levels of several metabolites by
1H-NMR (Figures 4, 5 and Supplementary Figure 2).
The intracellular metabolites were analyzed comparing the
effect of cysteine in the metabolic profile of cells cultured in
hypoxia with cells cultured in normoxia, in order to determine
the variations in organic compounds driven by the presence of
cysteine in both environments.
Regarding hypoxic ES2 cells, cysteine increased the
intracellular levels of the amino acids alanine (p = 0.009),
glutamate (p = 0.012), glycine (p = 0.008) and threonine
(p = 0.016) (Figure 4A). Cysteine also led to increased
intracellular levels of lactate (p = 0.021) (Figure 5B),
choline (p = 0.005) and creatine (p = 0.005) (Figure 4C).
In the extracellular media (supernatants), Co2+ employed
to elicit hypoxia reacted as expected with histidine and
therefore precluded any conclusion regarding histidine uptake
(Supplementary Figure 2C). Cysteine decreased the release of
fumarate under hypoxia (p = 0.046) (Figure 4E).
Through metabolic pathway analysis, results predicted that
nine metabolic pathways are significantly and differently
altered in ES2 cells by cysteine and hypoxia. The analysis
showed alteration in the biosynthetic pathways of: (1) glycine,
serine and/threonine; (2) alanine, aspartate and glutamate; (3)
glutamine and glutamate; (4) arginine and proline; (5) GSH; (6)
primary bile acid; (7) glycerophospholipid; (8) aminoacyl-tRNA;
and (9) purine nitrogen bases (Figure 4G).
Regarding OVCAR3 cells, the only significant difference found
on the effect of cysteine and hypoxia on intracellular metabolites
concentration was on glucose levels, where there was a decrease
in the intracellular levels of glucose (p = 0.021) (Figure 5).
However, cysteine and hypoxia also provided a general tendency
for increased intracellular amino acids such as alanine, glutamate,
tyrosine and valine (Figure 5A). The measurement of the levels
of these amino acids in the cell culture media showed that
OVCAR3 cells uptake lower levels of alanine (p = 0.023) and
proline (p = 0.008) and higher levels of glycine (p = 0.013) and
phenylalanine (p = 0.049) due to the exposure to cysteine and
hypoxia (Figure 5D). Cysteine and hypoxia also decreased the
release of 2-hydroxybutyrate (p< 0.001), formate (p = 0.002) and
isobutyrate (p < 0.001) (Figure 5E). As observed in ES2 cells,
cysteine seemed to induce the release of glutamine, especially
under normoxia (Supplementary Figure 2C).
The metabolite pathway analysis was not performed for
OVCAR3 cells because cysteine and hypoxia only altered
significantly one metabolite (glucose), thus making this
analysis inaccurate.
Importantly, in the absence of cysteine, hypoxia did not alter
the intracellular and extracellular levels of glucose and lactate in
both cell lines, whereas it led to a decreased uptake of glutamine
(p = 0.032) and to an increased release of fumarate (p = 0.041) in
OVCAR3 cells (Supplementary Figure 2D).
Cysteine Supplies Crucial Metabolic
Pathways in ES2 Cells, Under Normoxia
and Hypoxia
To clarify the role of cysteine as a carbon source, we
followed the metabolites directly derived from cysteine, by using
13C-L-cysteine. Our results supported that ES2 cells convert
cysteine into lactate (Figures 6A,B). Whereas we observed the
presence of satellite resonances indicating double 13C-labeled
lactate (13CH313CH(OH)COOH) in ES2 spectra, these were not
observed in OVCAR3 (Figure 6A). The presence of 13C satellite
resonances in the lactate is a direct result of 13C-L-cysteine
conversion into lactate. Furthermore, total (single and double-
labeled) 13C-lactate and the percentage of double-labeled 13C-
lactate tended to be higher under normoxia (NC 13C and NC
double 13C, respectively) compared to hypoxia (HC 13C and HC
double 13C, respectively) (Figure 6B). We also observed that
ES2 cells tended to consume glucose faster than OVCAR3 cells
both under normoxia and hypoxia in the presence of cysteine
(Figure 6C).
Furthermore, our results indicated that ES2 cells convert
cysteine mainly in GSH (GSH-CYS), lactate (Lac-3) and acetyl-
CoA (A-CoA). Small amounts of alanine (Ala3) and glutamate
(Glu4) and of other two unidentified compounds (Unk1 and
Unk2) were also detected (Figure 6D).
Finally, under normoxia, ES2 cells (ES2 NC) presented
cysteine in solution instead of cystine, and produced different
unknown compounds, while under hypoxia (ES2 HC) the main
compound presented was cystine. In the case of OVCAR3
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FIGURE 3 | Cysteine, but not NaHS, is able to rescue the ATP synthesis impairment, after 48 h under hypoxia triggered by xCT inhibition. (A–C) ATP levels for 1 h of
experimental conditions for (C). ES2 and OVCAR3 cells under hypoxia with and without cysteine and in the presence of the H2S donor, NaHS sulfasalazine in
which n = 5 for ES2; and H sulfasalazine and H NaHS C sulfasalazine, in which n = 5 for OVCAR3. (D,E) ATP levels for 48 h of experimental (un-normalized data),
and (D) ES2 and (E) OVCAR3 cells under hypoxia with and without cysteine supplementation and in the presence of the xCT inhibitor, conditions for (A) ES2
and (B) OVCAR3 cells under hypoxia with and without cysteine and in the presence of the xCT inhibitor, sulfasalazine and the H2S donor, NaHS. Data were
normalized to the respective control condition (the same environmental condition H/HC without NaHS or sulfasalazine). Data are presented as log2 fold change
(n = 6 for both cell lines). H, hypoxia; HC, hypoxia with cysteine. Results are shown as mean ± SD. ∗/p < 0.05, ∗∗/##p < 0.01, and ∗∗∗/###p < 0.001 [one-way
ANOVA with post hoc Tukey tests for (A,B,D,E) and independent-samples t-test for (C)].
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FIGURE 4 | Cysteine rescues ES2 cellular metabolism and impacts several metabolic pathways under hypoxia. (A–F) Metabolites levels for 48 h of experimental
conditions for ES2 cells. (A) Intracellular amino acids; (B) intracellular sugars and organic acids; (C) other intracellular metabolites; (D) amino acids in supernatants;
(E) sugars and organic acids in supernatants; (F) other metabolites in supernatants. Data were normalized to the respective control condition (the same
environmental condition NC/N and HC/H). NC, normoxia with cysteine; HC, hypoxia with cysteine. Results are shown as median with 25th to 75th percentiles.
*p < 0.05, **p < 0.01, ***p < 0.001 (independent-samples t-test: NC, n = 6; HC, n = 5). (G) Metabolic pathway analysis for the effect of cysteine under normoxia
and hypoxia in intracellular ES2 metabolites. All the matched pathways are displayed as circles. The color and size of each circle are based on p-value and pathway
impact value, respectively. The most impacted pathways having statistical significance (p < 0.05) are indicated. Source: https://www.metaboanalyst.ca/Metabo
Analyst/faces/home.xhtml.
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FIGURE 5 | Effect of cysteine in OVCAR3 metabolites under normoxia and hypoxia. Metabolites levels for 48 h of experimental conditions for OVCAR3 cells.
(A) Intracellular amino acids; (B) intracellular sugars and organic acids; (C) other intracellular metabolites; (D) amino acids in supernatants; (E) sugars and organic
acids in supernatants; (F) other metabolites in supernatants. Data were normalized to the respective control condition (the same environmental condition NC/N and
HC/H). NC, normoxia with cysteine; HC, hypoxia with cysteine. Results are shown as median with 25th to 75th percentiles. *p < 0.05, **p < 0.01, ***p < 0.001
(independent-samples t-test: NC, n = 6; HC, n = 6).
cells the profile was similar both under normoxia (OVCAR3
NC) and hypoxia (OVCAR3 HC), with cystine being the most
representative compound (Figure 6E).
DISCUSSION
In this work, we provide novel data supporting that cysteine
promotes sulfur and carbon metabolism reprogramming,
underlying the adaptation to hypoxic microenvironment in
ovarian cancer cells.
As a solid tumor grows, cancer cells are exposed to regions of
hypoxia, long established as a stimulus for tumor progression and
resistance to therapy (Vaupel and Mayer, 2007; Semenza, 2012).
We have recently proposed that cysteine allows adaptation to
hypoxic environments and also contributes to escape from
carboplatin-induced death in ovarian cancer cells (Nunes et al.,
2018a,b). In here, we aimed to investigate the mechanisms by
which cysteine protects ovarian cancer cells under hypoxia,
by addressing its role in cellular metabolism, namely through
energy production.
Uptake of cystine, the oxidized form of cysteine, is mediated by
xCT (solute carrier family 7 member 11 – SLC7A11), a member
of the cystine-glutamate transporter xc- system (Sato et al., 2000).
Intracellularly, cystine is reduced to cysteine, which is the rate-
limiting substrate for GSH synthesis, making xCT pivotal in the
cellular redox balance maintenance (reviewed in Conrad and
Sato, 2012). Herein, we have shown mitochondrial localization of
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FIGURE 6 | Cysteine is directly used by ES2 cells in the main metabolic pathways. (A) Highlight of the lactate methyl group resonance on the 13C-NMR spectra of
48 h culture media incubated with U-13C-cysteine. On the left panel, ES2 cells under normoxia (upper spectra) and under hypoxia (lower spectra); on the right panel,
OVCAR3 cells under normoxia (upper spectra) and under hypoxia (lower spectra). (B) Production of lactate by ES2 cells in culture media at different time points (12,
24, 36, and 48 h). (C) Glucose consumption in ES2 and OVCAR3 cells. (D) Resonances areas of the 13C-1H-HSQC projection on 13C spectra normalized by TSP
area in the cell extracts. (E) Highlight of 13C-1H-HSQC spectra of the growth media at 48 h incubation in the presence of U-13C-cysteine under normoxia and
hypoxia conditions. NC, normoxia with cysteine; HC, hypoxia with cysteine. (B–D) Results are shown as mean ± SD. Assays were performed in biological triplicates.
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the xCT transporter concomitant with impaired ATP production
triggered by its pharmacological inhibition under hypoxia, thus
indicating a role of the xc- system via cystine uptake also in energy
production. These data are in accordance with recent findings
supporting a role of Nrf2 in the regulation of mitochondrial ATP
synthesis (reviewed in Vomund et al., 2017). As a transcription
factor, Nrf2 was already reported to regulate the expression of
xCT and the activity of the xc- system in response to oxidative
stress in human breast cancer cells (Habib et al., 2015).
Cysteine’s role in mitochondrial ATP synthesis might be
associated to its non-oxidative metabolism resulting in H2S
(via CBS, CSE or MpST) and/or CysSSH (via CARS2) release.
H2S is the only inorganic compound presenting a bioenergetic
role in mammalian cells’ mitochondria (Goubern et al., 2007),
that was already reported to contribute to mitochondrial ATP
production through the activity of the enzymes involved in
cysteine metabolism: MpST in conjunction with CAT (Módis
et al., 2013a,b; Abdollahi Govar et al., 2020; Augsburger
et al., 2020), CSE (Fu et al., 2012), and CBS (Bhattacharyya
et al., 2013; Szabo et al., 2013). At low concentrations (nM),
H2S is known to stimulate mitochondrial bioenergetics by
way of different mechanisms: through donation of electron
equivalents to the quinol pool via sulfide:quinone oxidoreductase
(SQR); by the glycolytic enzyme glyceraldehyde 3-phosphate
dehydrogenase activation, and by persulfidation of ATP synthase
(reviewed in Giuffrè and Vicente, 2018). In addition, Li and
Yang (2015) reported a role of CSE/H2S system in enhancing
mtDNA replication and cellular bioenergetics both in smooth
muscle cells and mouse aorta tissues. In fact, this can be an
explanation for the increased number of mitochondria in ES2
cells under hypoxia, as the mitochondrial marker/endogenous
control TOMM20 is overexpressed. More recently, Chakraborty
et al. (2018) reported a new role of CBS in the regulation of
mitochondria morphogenesis, promoting tumor progression in
ovarian cancer. Specifically under hypoxia conditions, H2S was
reported to decrease reactive oxygen species (ROS), mediated
by CBS mitochondrial accumulation (Teng et al., 2013) and
induce ATP production, mediated by CSE translocation into
the mitochondria (Fu et al., 2012). A different adaptive strategy
to hypoxia has been reported by Malagrinò et al. (2019)
for the colorectal cancer cell line SW480, which exhibited a
lower mitochondrial mass in response to hypoxia, although
the mitochondria were enriched in H2S-disposal capacity
via increased mitochondrial SQR expression. This increased
mitochondrial SQR renders hypoxic SW480 cells more equipped
to inject H2S-derived electron equivalents into the mitochondrial
electron transfer chain and sustain mitochondrial bioenergetics.
In our study, short (2–16 h) exposure to CBS and CSE
inhibitors did not afford significant differences in ATP levels
in both cell lines, with the exception of OVCAR3 cells at
2 h under hypoxia with cysteine supplementation in which
the inhibitors led to decreased ATP levels (Supplementary
Figure 3A). Hence, OVCAR3 cells, under hypoxia, may channel
the extra cysteine to degradation, thereby producing H2S and/or
CysSSH, and enhancing ATP production. Despite the absent
effects at shorter times, the observed increased ATP levels at
prolonged (48 h) exposure to CBS and CSE inhibitors indicates
that the inhibition of both enzymes allows for compensatory or
alternative mechanisms of energy production, probably including
CAT/MpST and/or CARS2 activity. Given the fact that both CBS
and CSE have been reported to partially relocate to mitochondria
in hypoxia (Fu et al., 2012; Teng et al., 2013), available cysteine
may be converted in the mitochondria to H2S by CBS, CSE and
MpST, or to CysSSH by CARS2. Additionally, cystine can be
converted to CysSSH and pyruvate by CBS and CSE. Therefore,
whereas excess cysteine may trigger over-production of H2S
and/or CysSSH via CBS and CSE to the point they inhibit
the mitochondrial electron transfer chain and thereby impair
ATP production, in the presence of their inhibitors AOAA and
PAG, this inhibitory effect is likely released and ‘safer’ cysteine-
degradation mechanisms can be deployed, linked to stimulation
of ATP production.
Under hypoxia we did not observe differences in MpST
protein levels in both cell lines (Supplementary Figure 3B),
although we observed a mitochondrial MpST enrichment
compared to the cytosolic content (Supplementary Figure 3C).
Given that cysteine is a poor co-substrate for MpST as sulfane
sulfur acceptor to generate CysSSH with respect to other
possible co-substrates such as thioredoxin, the excess cysteine
load imposed on hypoxic cells may push the CAT/MpST
system into higher – yet controlled – CysSSH/H2S production.
Interestingly, enzymatic studies performed in E. coli showed
that a bacterial MpST homolog abrogates oxidative stress via
L-cysteine (Mironov et al., 2017). Another hypothesis is that
diversion of cysteine for CARS2-mediated generation of CysSSH
affords a protective role from cysteine oxidation in oxidative
stress triggered by hypoxic conditions, as recently shown by
Zivanovic et al. (2019) regarding the cysteine persulfidation
prevention of protein cysteine oxidative damage.
Considering the relevance of cysteine in ATP production,
our results showed that cysteine metabolism may operate in a
more intricate manner than simply increased H2S production
and concurrent ATP production. Although some studies showed
that NaHS, an exogenous H2S source, was sufficient to increase
mitochondrial ATP production under hypoxia (Fu et al., 2012),
our results showed that H2S per se was not sufficient to counteract
the impaired ATP production driven by sulfasalazine (xCT
inhibitor), under hypoxia in both ES2 and OVCAR3 cells.
Therefore, our experiments support that cysteine metabolism,
dependent on xCT transporter, provides alternative sources for
energy production in ovarian cancer cells (Figure 7A).
The synthesis of GSH is another way of cysteine contributing
for ATP production. The incorporation of extra cysteine in GSH
allows cells to escape from oxidative stress and enables increased
cell viability and proliferation, therefore leading to increased
ATP synthesis. In fact, our previous data have supported
a role of a higher thiols turnover in hypoxia adaptation,
especially in ES2 cells (Nunes et al., 2018b). Interestingly,
H2S was also reported to increase the production of GSH by
inducing the expression of cystine/cysteine transporters and by
redistributing GSH to mitochondria in mouse neuronal cell
models (Kimura et al., 2010).
Despite the fact that in addition to H2S and CysSSH
production, cysteine and cystine catabolism generate pyruvate
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FIGURE 7 | Cysteine possible direct and indirect roles in ATP synthesis and in carbon metabolism reprogramming under hypoxia in ovarian cancer cells. (A) Under
hypoxia, cysteine degradation could contribute directly to ATP production via not only H2S generation, but also via pyruvate and α-ketobutyrate that could further
supply the TCA cycle, leading to increased ATP synthesis. Cysteine could also present an indirect role in ATP synthesis mediated by increasing GSH content under
hypoxia, hence counteracting oxidative stress and thereby increasing cellular metabolism. Cystine can also be converted into cysteine persulfide (CysSSH) by CSE
and CBS in the cytoplasm or by CSE, CBS and CARS2 in the mitochondria. (B) The axis cysteine-pyruvate-glucose is central in whole metabolic network of carbon.
Cysteine degradation can originate pyruvate and glutamate. Pyruvate besides being a major supplier of tricarboxylic acids (TCA) cycle, it can be converted into
valine, isoleucine, leucine, alanine, lactate, and acetate. Alanine can be a source of glucose through gluconeogenesis. Glycolysis produce intermediates to supply the
TCA cycle (a hub for many precursors of organic compounds, such as threonine) and the pentose phosphate pathway (PPP). PPP intermediates can be converted
into amino acids such as histidine and can be conjugated with glycolysis intermediates, originating tyrosine, phenylalanine and serine, which can be converted into
glycine. PPP is also crucial in the nucleotide’s synthesis. Acetyl-CoA is a central organic compound in metabolism, when cysteine-derived it proves that cysteine is a
valuable supplier of TCA cycle and amino acids and fatty acids syntheses. The increased concentration of these compounds under hypoxia, suggests that cysteine
is pushing the metabolic flow in order to supply the main carbon metabolic pathways. The direct incorporation of cysteine into these compounds is possible,
however, further studies are needed to clarify this. Based on information from www.bioinfo.org.cn.
as well (Wang, 2012; Bonifácio et al., 2020), cysteine is
not commonly considered as a carbon source. Herein,
we showed that cysteine gives rise to lactate by being
firstly converted into pyruvate and alanine, indicating that
cysteine could also be used in gluconeogenesis (Figure 7B).
Most importantly, cysteine also originates acetyl-CoA,
which is a central metabolite, supplying the TCA cycle,
fatty acids synthesis and amino acids synthesis. Our study
reinforces that cysteine can account for biosynthesis and
bioenergetics not only as a sulfur source but also as a
carbon donor.
Importantly, Beaufort et al. (2014) characterized 39 ovarian
cancer cell lines in order to correlate the cellular and molecular
features with their tumorigenic phenotype. In that study, ES2,
but not OVCAR3, was included in the most aggressive subset
of ovarian cancer cells (Beaufort et al., 2014). In here, our data
supported that cysteine orchestration in metabolic remodeling
and plasticity can be a crucial phenomenon for more aggressive
cancer cells phenotype. Strikingly, 1H-NMR results showed that
the metabolic impact of cysteine under hypoxia was much more
pronounced in ES2 cells than in OVCAR3 cells, translated by the
remarkable number of metabolic pathways that were significantly
altered. Therefore, taken together, our results reinforced the
role of cysteine as a valuable carbon source, from which cancer
cells take advantage on the course of the metabolic rewiring
they undergo under hypoxia. In particular, cysteine is a central
carbon source for ES2 cells, supporting their redox capacity
by supplying GSH synthesis and allowing the maintenance of
pivotal biosynthetic and bioenergetic pathways dependent on
acetyl-CoA. Furthermore, results suggested that under hypoxia,
cysteine allowed to increase the rate of some metabolic pathways
in ES2 cells, as increased intracellular levels of several amino
acids and other compounds were observed. Regarding OVCAR3
cells, results supported that cysteine impacts differently the
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cellular needs of amino acids under normoxia and hypoxia.
Moreover, when comparing to OVCAR3, results suggest that ES2
cells are better adapted to hypoxia and to the use of cysteine
to overcome the hypoxic stress, as seen by the higher number
of metabolic pathways that were significantly altered by cysteine
under hypoxia.
Interestingly, while cysteine was able to rescue the impaired
ATP synthesis triggered by xCT inhibition, it was not able
to increase ATP synthesis upon β-oxidation and glycolysis
inhibition (Supplementary Figure 3D), indicating that cysteine
is not enough to replace the contribution of these pathways
for ATP production.
Together, the results support that ES2 and OVCAR3
cells use cysteine differently in order to cope with hypoxia,
where cysteine especially impacts hypoxic ES2 cells metabolic
features, enhancing the metabolic reprogramming. In Figure 7,
we present the possible direct and indirect pathways
in which cysteine can be a metabolic coin, promoting
ATP production in hypoxic ovarian cancer cells. The
profound metabolic impact that cysteine showed under
hypoxia in ES2 cells suggests a strong remodeling of the
carbon metabolism.
This work lights again that disturbing cysteine metabolic
network can be a promising tool not only in ovarian cancer
but also in all cancer models that rely their survival on cysteine
bioavailability and metabolic versatility.
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